Communiqués Rani Therapeutics Holdings, Inc.

Actions

RANI

US7530181004

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 24/07/2026			Varia. 5j.	Varia. 1 janv.
0,8509 ^USD	-4,39%		+22,03%	-36,97%

15/07	Rani Therapeutics publie des données initiales positives de phase 1a pour le RT-114 dans le traitement de l'obésité	CI
15/07	Rani Therapeutics publie des données initiales positives de phase 1a pour le RT-114 dans le traitement de l'obésité	MT

Communiqués

20/07	Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
15/07	Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing	AQ
09/07	Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates	AQ
29/06	Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer	AQ
26/05	Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules	AQ
15/05	Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition	AQ
12/05	Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference	AQ
09/04	Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy	AQ
26/03	Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update	AQ
25/03	Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization	AQ
19/03	Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results	AQ
28/01	Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer	AQ
27/01	Rani Therapeutics : Corporate Presentation January 2026	PU
08/01	Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen	AQ
24/11	Rani Therapeutics to Participate in the Evercore Healthcare Conference	AQ
06/11	Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update	AQ
31/10/25	Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill Capsule at ObesityWeek 2025	AQ
30/10/25	Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025	AQ
23/10/25	Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors	AQ
23/10/25	Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules	AQ
17/10/25	Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules	AQ
17/10/25	Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing	AQ
07/08/25	Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update	AQ
15/07/25	Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering	AQ
14/07/25	Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery	AQ